Discover all the insulin options available from Novo Nordisk
Novo Nordisk offers a variety of insulin options to help people with diabetes control their blood sugar. Here, you can find information on insulin products and diabetes, as well as details on how to save on insulin and sign up for a personalized diabetes management support program.
Tresiba® is a long-acting insulin used to control high blood sugar in both adults and children with type 1 and type 2 diabetes over 1 year of age.
Product
Information
Get a
Savings Card
Interested in another Novo Nordisk insulin product?
Find insulin products that fit your needs, as well as other information specifically tailored for your diabetes treatment.
See your diabetes options
Levemir® is a long-acting insulin indicated to improve glycemic control in adults and children with diabetes.
Fiasp® is a mealtime insulin with dose-time flexibility used to control high blood sugar in adults and children with diabetes.
NovoLog® is a mealtime insulin used to control high blood sugar in adults and children with diabetes.
NovoLog® Mix 70/30 is a premixed insulin used to control blood sugar in adults with diabetes.
Xultophy® 100/3.6 is a combination of long-acting insulin and a glucagon-like peptide-1 receptor agonist (GLP-1 RA) used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.
What is Tresiba® (insulin degludec injection) 100 U/mL, 200 U/mL?
Do not share your Tresiba® FlexTouch® with other people, even if the needle has been changed. Do not share needles or syringes with another person. You may give other people a serious infection, or get a serious infection from them.
Do not take Tresiba® if you:
Before taking Tresiba®, tell your health care provider about all your medical conditions, including if you are:
Talk to your health care provider about low blood sugar and how to manage it.
Tresiba® may cause serious side effects that can be life-threatening, including:
Your insulin dose may need to change because of change in level of physical activity or exercise, increased stress, change in diet, weight gain or loss, or illness.
Get emergency medical help if you have trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, or confusion.
Please click here for Prescribing Information.
Do not share your Levemir® FlexPen® with other people, even if the needle has been changed. Do not share needles or syringes with another person. You may give other people a serious infection or get a serious infection from them.
Do not take Levemir® if:
Before taking Levemir®, tell your health care provider about all your medical conditions including, if you:
Tell your healthcare provider all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Before you start taking Levemir®, talk to your health care provider about low blood sugar and how to manage it.
Serious side effects can lead to death, including:
Other common side effects include:
Your insulin dose may need to change because of:
Please click here for Levemir® Prescribing Information.
Do not share your Fiasp® with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
Do not take Fiasp® if:
Before taking Fiasp® tell your health care provider about all your medical conditions including, if you:
Talk to your health care provider about low blood sugar and how to manage it.
Serious side effects can lead to death, including:
Your insulin dose may need to change because of:
Common side effects of Fiasp® may include:
Do not share your Fiasp® with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
Do not take Fiasp® if:
Before taking Fiasp® tell your health care provider about all your medical conditions including, if you:
Talk to your health care provider about low blood sugar and how to manage it.
Please click here for Fiasp® Prescribing Information.
Do not share your NovoLog® FlexPen®, NovoLog® FlexTouch®, PenFill® cartridge or PenFill® cartridge compatible insulin delivery device with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
Do not take NovoLog® if:
Before taking NovoLog®, tell your health care provider about all your medical conditions including, if you are:
Talk to your health care provider about how to manage low blood sugar.
Serious side effects can lead to death, including:
Low blood sugar. Some signs and symptoms include:
Your insulin dose may need to change because of:
Other common side effects may include:
Get emergency medical help if you have:
Please click here for NovoLog® Prescribing Information.
Do not share your NovoLog® Mix 70/30 FlexPen® with other people, even if the needle has been changed. Do not share needles or syringes with another person. You may give other people a serious infection, or get a serious infection from them.
Before taking NovoLog® Mix 70/30, tell your healthcare provider about all your medical conditions including, if you are:
Before you start taking NovoLog® Mix 70/30, talk to your health care provider about low blood sugar and how to manage it.
Serious side effects can lead to death, including:
Low blood sugar (hypoglycemia). Some signs and symptoms include:
Your insulin dose may need to change because of:
Other common side effects may include:
Get emergency medical help if you have:
Please click here for NovoLog® Mix 70/30 Prescribing Information.
Xultophy® 100/3.6 is an injectable prescription medicine that contains 2 diabetes medicines, insulin degludec, 100 units/mL, and liraglutide, 3.6 mg/mL. Xultophy® 100/3.6 should be used along with diet and exercise to lower blood sugar (glucose) in adults with type 2 diabetes mellitus.
Xultophy® 100/3.6 may cause serious side effects, including:
Do not use Xultophy® 100/3.6 if:
Tell your health care provider about all your medical conditions, including if you:
Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Before using Xultophy® 100/3.6, talk to your health care provider about low blood sugar and how to manage it.
Your dose of Xultophy® 100/3.6 may need to change because of change in level of physical activity or exercise, weight gain or loss, increased stress, illness, change in diet, or other medicines you take.
Xultophy® 100/3.6 may cause serious side effects that can be life-threatening, including:
The most common side effects of Xultophy® 100/3.6 may include stuffy or runny nose, sore throat, headache, nausea, diarrhea, increased blood levels of lipase, and upper respiratory tract infection.
Xultophy® 100/3.6 is an injectable prescription medicine that contains 2 diabetes medicines, insulin degludec, 100 units/mL, and liraglutide, 3.6 mg/mL. Xultophy® 100/3.6 should be used along with diet and exercise to lower blood sugar (glucose) in adults with type 2 diabetes mellitus.
Please see full Prescribing Information and Medication Guide for Xultophy® 100/3.6.
What is Tresiba® (insulin degludec injection) 100 U/mL, 200 U/mL?
Do not share your Tresiba® FlexTouch® with other people, even if the needle has been changed. Do not share needles or syringes with another person. You may give other people a serious infection, or get a serious infection from them.
Do not take Tresiba® if you:
Before taking Tresiba®, tell your health care provider about all your medical conditions, including if you are:
Talk to your health care provider about low blood sugar and how to manage it.
Tresiba® may cause serious side effects that can be life-threatening, including:
Your insulin dose may need to change because of change in level of physical activity or exercise, increased stress, change in diet, weight gain or loss, or illness.
Get emergency medical help if you have trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, or confusion.
Please click here for Prescribing Information.
Do not share your Levemir® FlexPen® with other people, even if the needle has been changed. Do not share needles or syringes with another person. You may give other people a serious infection or get a serious infection from them.
Do not take Levemir® if:
Before taking Levemir®, tell your health care provider about all your medical conditions including, if you:
Tell your healthcare provider all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Before you start taking Levemir®, talk to your health care provider about low blood sugar and how to manage it.
Serious side effects can lead to death, including:
Other common side effects include:
Your insulin dose may need to change because of:
Please click here for Levemir® Prescribing Information.
Do not share your Fiasp® with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
Do not take Fiasp® if:
Before taking Fiasp® tell your health care provider about all your medical conditions including, if you:
Talk to your health care provider about low blood sugar and how to manage it.
Serious side effects can lead to death, including:
Your insulin dose may need to change because of:
Common side effects of Fiasp® may include:
Do not share your Fiasp® with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
Do not take Fiasp® if:
Before taking Fiasp® tell your health care provider about all your medical conditions including, if you:
Talk to your health care provider about low blood sugar and how to manage it.
Please click here for Fiasp® Prescribing Information.
Do not share your NovoLog® FlexPen®, NovoLog® FlexTouch®, PenFill® cartridge or PenFill® cartridge compatible insulin delivery device with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
Do not take NovoLog® if:
Before taking NovoLog®, tell your health care provider about all your medical conditions including, if you are:
Talk to your health care provider about how to manage low blood sugar.
Serious side effects can lead to death, including:
Low blood sugar. Some signs and symptoms include:
Your insulin dose may need to change because of:
Other common side effects may include:
Get emergency medical help if you have:
Please click here for NovoLog® Prescribing Information.
Do not share your NovoLog® Mix 70/30 FlexPen® with other people, even if the needle has been changed. Do not share needles or syringes with another person. You may give other people a serious infection, or get a serious infection from them.
Before taking NovoLog® Mix 70/30, tell your healthcare provider about all your medical conditions including, if you are:
Before you start taking NovoLog® Mix 70/30, talk to your health care provider about low blood sugar and how to manage it.
Serious side effects can lead to death, including:
Low blood sugar (hypoglycemia). Some signs and symptoms include:
Your insulin dose may need to change because of:
Other common side effects may include:
Get emergency medical help if you have:
Please click here for NovoLog® Mix 70/30 Prescribing Information.
Xultophy® 100/3.6 is an injectable prescription medicine that contains 2 diabetes medicines, insulin degludec, 100 units/mL, and liraglutide, 3.6 mg/mL. Xultophy® 100/3.6 should be used along with diet and exercise to lower blood sugar (glucose) in adults with type 2 diabetes mellitus.
Xultophy® 100/3.6 may cause serious side effects, including:
Do not use Xultophy® 100/3.6 if:
Tell your health care provider about all your medical conditions, including if you:
Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Before using Xultophy® 100/3.6, talk to your health care provider about low blood sugar and how to manage it.
Your dose of Xultophy® 100/3.6 may need to change because of change in level of physical activity or exercise, weight gain or loss, increased stress, illness, change in diet, or other medicines you take.
Xultophy® 100/3.6 may cause serious side effects that can be life-threatening, including:
The most common side effects of Xultophy® 100/3.6 may include stuffy or runny nose, sore throat, headache, nausea, diarrhea, increased blood levels of lipase, and upper respiratory tract infection.
Xultophy® 100/3.6 is an injectable prescription medicine that contains 2 diabetes medicines, insulin degludec, 100 units/mL, and liraglutide, 3.6 mg/mL. Xultophy® 100/3.6 should be used along with diet and exercise to lower blood sugar (glucose) in adults with type 2 diabetes mellitus.
Please see full Prescribing Information and Medication Guide for Xultophy® 100/3.6.
Tresiba® is a prescription medication.
Levemir® is a prescription medication.
Fiasp® is a prescription medication.
NovoLog® is a prescription medication.
NovoLog® Mix 70/30 is a prescription medication.
Xultophy® 100/3.6 is a prescription medication.
Autocover®, Fiasp®, FlexPen®, FlexTouch®, Levemir®, NovoCare®, NovoFine®, NovoLog®, NovoLog® Mix 70/30, NovoPen Echo®, PenFill®, Tresiba®, and Xultophy® are registered trademarks of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
© 2024 Novo Nordisk All rights reserved. US24TSM00013 June 2024